Another advantage of controlling MMP-3 levels is the reduced risk of osteoarthritis after ACL surgery, as is currently the case, where 45% of postoperative ACL reconstruction patients experience OA after 10 years [5]. The gene discussed is MMP3; the disease is osteoarthritis.